Acer Therapeutics (Acer Therapeutics) Revenue per Share : $0.00 (TTM As of Jun. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Acer Therapeutics Revenue per Share?

Acer Therapeutics's revenue per share for the three months ended in Jun. 2023 was $0.00. Acer Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

During the past 12 months, the average Revenue Per Share Growth Rate of Acer Therapeutics was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Acer Therapeutics's Revenue per Share or its related term are showing as below:

During the past 13 years, Acer Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was -15.10% per year. The lowest was -15.10% per year. And the median was -15.10% per year.

ACER's 3-Year Revenue Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 5.4
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Acer Therapeutics Revenue per Share Historical Data

The historical data trend for Acer Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acer Therapeutics Revenue per Share Chart

Acer Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Revenue per Share

Get a 7-Day Free Trial

0.09

Acer Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Revenue per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Acer Therapeutics's Revenue per Share

For the Biotechnology subindustry, Acer Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acer Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acer Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Acer Therapeutics's PS Ratio falls into.

Acer Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Acer Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2022 is calculated as

Revenue Per Share (A: Dec. 2022 )	=	Revenue (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	0	/	15.767
	=	0.00

Acer Therapeutics's Revenue Per Share for the quarter that ended in Jun. 2023 is calculated as

Revenue Per Share (Q: Jun. 2023 )	=	Revenue (Q: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Jun. 2023 )
	=	0	/	24.463
	=	0.00

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Acer Therapeutics (OTCPK:ACER) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Acer Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Acer Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Acer Therapeutics (Acer Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acer Therapeutics Inc (OTCPK:ACER) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458

Website

https://www.acertx.com

Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

Executives

Chris Schelling	director, officer: President and Chief Executive	C/O ACER THERAPEUTICS INC., 222 THIRD STREET, CAMBRIDGE MA 02142
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Tanya Hayden	officer: Chief Operating Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Adrian W Quartel	officer: Chief Medical Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Bernard H Paul	officer: Chief People Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Jefferson E Davis	officer: Chief Business Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
John Michael Dunn	director	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Donald Joseph	officer: Chief Legal Officer and Secy	C/O KALOBIOS PHARMACEUTICALS, INC., 260 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Michael Klopp	officer: Chief Technology Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Matthew Seibt	officer: Chief Commercial Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Harry S Palmin	officer: Chief Opp. and Financial Offr	C/O NOVELOS THERAPUETICS, INC., ONE GATEWAY CENTER,SUITE 504, NEWTON MA 02458
William T. Andrews	officer: Chief Medical Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Jason Amello	director	500 KENDALL STREET, CAMBRIDGE MA 01824
Salma Jutt-eghbali	officer: Chief Commercial Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458